In this article, we will list the 5 Best Dividend Aristocrat Stocks To Buy Now. Please visit 10 Best Dividend Aristocrat Stocks To Buy Now if you would like to see the extended list and the methodology behind it.
5. AbbVie Inc. (NYSE:ABBV)
Dividend Yield: 3.20%
Number of Hedge Fund Holders: 87
AbbVie Inc. (NYSE:ABBV) is one of the best dividend aristocrat stocks to buy now.
On June 19, AbbVie Inc. (NYSE:ABBV) delivered topline Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress. The results from the Phase 3 CLL14 trial affirm venetoclax’s enduring safety and efficacy in untreated chronic lymphocytic leukemia (CLL).
The trial results also affirm venetoclax plus obinutuzumab’s ability to improve progression-free survival (PFS) compared to chlorambucil plus obinutuzumab. Consequently, it affirms the candidate drug’s potential in patients living with difficult-to-cure blood cancers.
The positive clinical trial results come on the heels of AbbVie reiterating its commitment to shareholder value by declaring a $ 1.73-per-share quarterly dividend. The dividend is to be paid on August 14, 2026, to shareholders of record as of July 15, 2026.
AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company that discovers, develops, and delivers innovative medicines and therapies to treat complex, critical health issues worldwide. Spun off from Abbott in 2013, the company treats millions of people globally across five main areas of medicine.
4. Medtronic plc (NYSE:MDT)
Dividend Yield: 3.63%
Number of Hedge Fund Holders: 60
Medtronic plc (NYSE:MDT) is one of the best dividend aristocrat stocks to buy now.
On June 5, Cardiovascular intelligence software company Retia Medical expanded its commercial relationship with Medtronic plc (NYSE:MDT) to include the distribution of Argos Cardiac Output Monitor. Medtronic is to help Retia expand into new markets and bring its hemodynamic monitoring technology to clinicians managing high-risk surgical and critically ill patients.
The integration of Medtronic’s Acute Care & Monitoring Technologies, such as INVOS and accurate hemodynamic monitoring, will help clinicians personalize care in high-risk surgical and critically ill patients. The Argos Cardiac Output Monitor will also expand the company’s portfolio while providing meaningful cardiovascular insights.
Medtronic and Retia have set their sights on the European market, as it is one of the most important critical care markets, having built a strong clinical foundation in the US.
Medtronic plc (NYSE:MDT) is a global healthcare technology leader that engineers and manufactures medical devices and therapies to treat over 70 health conditions. Their technologies range from pacemakers and insulin pumps to surgical robotics, improving lives for millions worldwide.
3. Chevron Corporation (NYSE:CVX)
Dividend Yield: 4.07%
Number of Hedge Fund Holders: 103
Chevron Corporation (NYSE:CVX) is one of the best dividend aristocrat stocks to buy now.
On June 23 at the J.P. Morgan Natural Resources Conference, Jeff Gustavson, President of Chevron Corporation (NYSE:CVX), New Energies, reiterated a heightened focus on low-carbon technologies, including carbon capture, renewable fuels, lithium, and hydrogen.
The push is part of a drive that seeks to meet global energy demand while also delivering shareholder value. While Chevron is the largest natural gas producer in the US, Gustavson expects the company to capitalize on the soaring power demand by leveraging its LNG business. The executive also reiterated that partnerships with the likes of GE Vernova and Caterpillar on equipment, and now Microsoft on data centers, position the company to generate significant value while meeting growing energy demands.
The company’s subsidiary, Energy Forge One LLC, is poised to build a 2.67 GW natural gas-powered facility co-located with Microsoft’s data center campus as part of the Kilby project.
Chevron Corporation (NYSE:CVX) is a multinational energy corporation that explores, produces, and transports crude oil and natural gas, and refines them into everyday products like gasoline and plastics. Alongside traditional fossil fuels, the company operates gas stations and invests in lower-carbon technologies like hydrogen, solar, and bioenergy.
2. PepsiCo, Inc. (NASDAQ:PEP)
Dividend Yield: 4.17%
Number of Hedge Fund Holders: 72
PepsiCo, Inc. (NASDAQ:PEP) is one of the best dividend aristocrat stocks to buy now.
On June 11, PepsiCo (NASDAQ:PEP) announced its participation in RegenLend, a pilot program designed to help farmers adopt soil conservation practices by easing the financial burden of equipment costs. Developed in partnership with Compeer Financial, the Environmental Defense Fund (EDF), and the Soil and Water Outcomes Fund (SWOF), the initiative enables farmers to lease strip‑till equipment while PepsiCo covers two annual lease payments, directly reducing upfront expenses.
Strip‑till technology improves soil health, enhances water retention, and reduces erosion, while also lowering fuel and labor costs. However, the high initial investment has been a barrier for many farmers. By sharing costs, PepsiCo is helping accelerate the adoption of sustainable practices that strengthen the resilience of the agricultural supply chain.
PepsiCo’s sustainable agriculture lead, Caitlin Colegrove, emphasized that the company is committed to collaborating across the value chain to support farmers facing rising costs and climate challenges. The program reflects PepsiCo’s broader sustainability strategy, aligning supply chain incentives with long‑term environmental and economic benefits.
PepsiCo, Inc. (NASDAQ:PEP) is a global leader in convenient foods and beverages, operating in over 200 countries and territories. The company manufactures, markets, and distributes a wide range of iconic products, including beverages, snacks, and ready-to-drink meals.
1. Hormel Foods Corporation (NYSE:HRL)
Dividend Yield: 4.84%
Number of Hedge Fund Holders: 35
Hormel Foods Corporation (NYSE:HRL) is one of the best dividend aristocrat stocks to buy now.
On May 28, Hormel Foods Corporation (NYSE:HRL) delivered strong second-quarter results characterized by profitable growth and improved performance. The company achieved a sixth consecutive quarter of organic top-line growth and double-digit adjusted earnings growth.
Net sales in the year were up 3% to $2.97 billion, with diluted earnings per share of $0.29 and adjusted earnings per share of $0.40. Hormel Foods Corporation expects full-year net sales to range between $12.2 billion and $12.5 billion, with organic net sales growing by between 1% and 4%. The company has also reaffirmed adjusted diluted earnings per share of $1.43 to $1.51, reflecting growth of 4% to 10%.
During the quarter, the company completed the divestiture of its whole-bird turkey business. The transaction affirmed the company’s strategic shift towards expanding its value-added protein portfolio and reducing exposure to more volatile businesses.
Hormel Foods Corporation (NYSE:HRL) is a multinational branded food company that manufactures and markets a wide variety of meat and grocery products worldwide. Their portfolio spans retail, foodservice, and international markets, supplying everything from canned meals and deli meats to peanut butter.
While we acknowledge the potential of HRL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than HRL and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 UK Stocks with the Highest Dividends and 10 Best Falling Stocks to Invest In According to Analysts.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
